Abnormal Uterine BleedingBARHYSTERNCT06024109
Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
An observational study of Abnormal Uterine Bleeding and Endometriosis, run by Aesculap AG at 2 sites in 2 countries.
Trial summary
The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Abnormal Uterine Bleeding, Endometriosis, Uterine Prolapse
- What is being tested?
- Closure of the Vaginal Cuff after Total Hysterectomy
- Type of treatment
- Medical device
- How many people
- 132 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 19 Mar 2024to Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Study population: Female patients undergoing an elective, laparoscopic total hysterectomy
Who may be able to join
- Females undergoing an elective, laparoscopic total hysterectomy
- Age ≥ 18 years
- Written informed consent
Who cannot join
- Emergency surgery
- Open surgery
- Patients undergone immunosuppressive drug treatment within the prior 6 months
- Patients with hypersensitivity or allergy to the suture material.
- Participation in another clinical study
- Non-compliance of patient
Trial locations and contacts
2 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
2 sites in 2 countries
Germany1 site, 1 recruiting
- Recruiting
Klinikum Sachsenhausen der DGD
Frankfurt am Main, Hesse, 60594
Amadeus Hornemann, Prof. Dr.
Amadeus Hornemann, Prof. Dr.
Spain1 site, 1 recruiting
- Recruiting
Hospital Sant Joan de Déu de Manresa
Manresa, Barcelona, 08243
Lourdes Hinojosa Sánchez, Dra.
Lourdes Hinojosa Sánchez, Dra.
About this study
Official title: Prospective, International, Randomized, Multicentric, Controlled Study on the Performance of SYMMCORA® Mid-term Unidirectional Barbed Suture Versus V-loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate.
Secondly, the superiority of SYMMCORA®, mid-term unidirectional compared to the V-Loc®, unidirectional will be assessed regarding the mean time to close the vaginal cuff. The study will be performed in routine clinical setting, the only difference will be the randomization into two different suture groups. Both suture materials which will be applied to approximate the vaginal cuff are approved and carrying the CE-marks. Additionally, both sutures will be applied in their intended use. Neither additional invasive measures nor additional burden in regard to the patient will be performed.
- Conditions
- Abnormal Uterine Bleeding, Endometriosis, Uterine Prolapse, Uterine Cancer, Ovarian Cancer, Fallopian Tube Cancer
- Being tested
- Closure of the Vaginal Cuff after Total Hysterectomy
- Keywords
- Barbed Suture, Hysterectomy, Laparoscopy, Minimal Invasive
- Medical subject headings
- Metrorrhagia, Endometriosis, Uterine Prolapse, Uterine Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Closure of the Vaginal Cuff after Total HysterectomyDevice
Also called Suturing
Closure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU).
| Study group | Role | What they receive |
|---|---|---|
| SYMMCORA® | Barbed suture SYMMCORA® used for the vaginal cuff closure in female patients undergoing total laparoscopic hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU). Receives: Device: Closure of the Vaginal Cuff after Total Hysterectomy | |
| V-Loc® | Barbed suture V-Loc® used for the vaginal cuff closure in female patients undergoing total laparoscopic hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU). Receives: Device: Closure of the Vaginal Cuff after Total Hysterectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Suturing time to close the vaginal cuff
Measured in Minutes. Time to perform the vaginal cuff closure after laparoscopic total hysterectomy using a stop watch. Time starts when the needle passes the first time the tissue and ends after completion of the wound closure (cut of the needle from the thread).
Measured: intraoperatively
Secondary outcomes (16)
Number of patients with early complications
Documented early complications include Hemoglobin drop and Fever more than 38°C within 48 hours
Measured: at discharge (up to 10 days after surgery)
Number of patients with complications over the study period
Documented complications include Vaginal cuff infection, Vaginal cuff dehiscence (Defined as a visually confirmed partial or complete opening of the vaginal stump with or without visceral organ herniation), Vaginal cuff granulation formation, Pelvic Abscess Formation, Hematoma, Vaginal spotting (defined as bloody vaginal discharge that did not require extraordinary procedures or medication and disappeared spontaneously. (Days of postoperative bleeding, Number of pads / tampons used), Vaginal bleeding (Defined as postoperative vaginal stump bleeding that required additional stump suture to stop bleeding. (Days of postoperative bleeding, number of pads / tampons used), Urinary tract infection, Bladder injury, Ureter injury, Bowel obstruction, Ileus, Cystitis and Pelvic Adhesions.
Measured: at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Number of patients with device deficiencies over the study period
Documented device deficiencies include Suture rupture, Knots in the thread, Connection between needle and thread not intact and Disconnection of the anchor from the thread
Measured: intraoperatively, at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Patient satisfaction (VAS 0-100) over time
The patient's self assessment of her satisfaction with the surgery. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "low" and "100" at the opposite end representing "high". The value is measured in [mm] with a ruler and documented in whole numbers.
Measured: at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Progress of Female Sexual Function Index (FSFI) compared to baseline
The Female Sexual Function Index (FSFI) is a 19-item, self-report measure of female sexual function that provides scores on overall levels of sexual function as well as the primary components of sexual function in women, including sexual desire, arousal, orgasm, pain, and satisfaction. The 19 items of the FSFI use a 5-point Likert scale ranging from 1-5 with higher scores indicating greater levels of sexual functioning on the respective item. (0 points in some cases for items that are not applicable). To score the measure, the sum of each domain score is first multiplied by a domain factor ratio (0.6 for desire; 0.3 for arousal and lubrication; 0.4 for orgasm, satisfaction and pain) in order to place all domain totals on a more comparable scale, and then subsequently summed to derive a total FSFI score. The domain scores range from 1.2 - 6, the overall score ranges from 7.2 - 36.
Measured: Preoperatively (baseline), at follow-up visits 6-8 weeks postoperatively and 6 months postoperatively
Overall operation time
From the first cut to the end of the surgery
Measured: intraoperatively
Cost of treatment
Calculation using the length of hospitalization (days until discharge), suturing time, suture costs and needed transfusions)
Measured: at discharge (approximately 10 days after surgery)
Length of postoperative hospital stay
calculated by subtracting the surgery date from the date of discharge
Measured: at discharge (approximately 10 days after surgery)
Progress of Patient's abdominal pain (VAS 0-100) compared to baseline
The patient's self assessment of her abdominal pain. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain". The value is measured in [mm] with a ruler and documented in whole numbers
Measured: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Progress of Patient's pelvic pain (VAS 0-100) compared to baseline
The patient's self assessment of her pelvic pain. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain". The value is measured in [mm] with a ruler and documented in whole numbers
Measured: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Progress of Patient's lumbar pain (VAS 0-100) compared to baseline
The patient's self assessment of her lumbar pain. This parameter will be noted using the Visual Analogue Scale (VAS), represented by a line 10 cm of length, which states "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain". The value is measured in [mm] with a ruler and documented in whole numbers
Measured: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Progress of General Health Status compared to baseline
The patient's self assessment of her general health status. Health status is based on assessment of the patient to the question, "Would you say your health in general is...:" The options are excellent / very good / good / fair / poor
Measured: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Patient assessment of postoperative Dyspareunia
Dyspareunia is defined by genital pain that can be experienced before, during, or after intercourse. The patient answers with yes or no.
Measured: at both follow-up visits (6-8 weeks postoperatively and 6 months postoperatively)
Assessment of the handling of the barbed suture (SYMMCORA®)
Assessment of the handling of the unidirectional barbed suture (SYMMCORA®) intra-operatively including eleven different dimensions (pliability, Pass-through, traumaticity, anchoring capacity, safety of closure, locking system size, locking system deployment, locking system unbarbed area, locking system safety of closure, atraumaticity, wound closure approximation) and an overall impression with 5 evaluations levels (excellent, very good, good, satisfied, poor).
Measured: intraoperatively
Assessment of the handling of the barbed suture (SYMMCORA®) compared to conventional suture
Assessment of the handling of the barbed suture (SYMMCORA®) compared to conventional suture regarding degree of difficulties and the ease of handling. (Likert Scale: strongly agree, agree, neither agree nor disagree, disagree, strongly disagree).
Measured: intraoperatively
Assessment of the handling of the barbed suture (SYMMCORA®) compared to barbed suture (V-Loc)
Assessment of the barbed suture (SYMMCORA®) compared to barbed suture (V-Loc®) regarding smoothness, suppleness, traumaticity of the thread, the handling, the opening of the package and the overall opinion (Likert Scale: worse, equal, better).
Measured: intraoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Sep 2023
- Study start19 Mar 2024
- Primary completionJan 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Abnormal Uterine BleedingStudies of the same condition, open and under way.
- More trials run by Aesculap AGThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 132 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Aesculap AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- B.Braun Surgical SA
- Responsible party
- Sponsor
- Investigators
- Amadeus Hornemann, Prof. Dr., Principal investigator, Klinikum Sachsenhausen der DGD
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06024109
- Sponsor's protocol ID
- AAG-O-H-2001
- Acronym
- BARHYSTER
- Status last verified
- Jun 2026
- First submitted
- 15 Aug 2023
- Last updated
- 2 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Baumann P, Sanchez LH, Garcia NG, Sologiuc L, Hornemann A. Assessment of a novel unidirectional mid-term absorbable barbed suture versus a competitor barbed suture for vaginal cuff closure after gynaecology surgery, study protocol of a randomized controlled trial - BARHYSTER. BMC Surg. 2025 Jan 14;25(1):23. doi: 10.1186/s12893-024-02700-z.
PubMed 39806425
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective, International, Randomized, Multicentric, Controlled Study on the Performance of SYMMCORA® Mid-term Unidirectional Barbed Suture Versus V-loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
- ClinicalTrials.gov ID
- NCT06024109
- Acronym / sponsor ID
- BARHYSTER / AAG-O-H-2001
- Conditions
- Abnormal Uterine Bleeding, Endometriosis, Uterine Prolapse, Uterine Cancer, Ovarian Cancer, Fallopian Tube Cancer
- Keywords
- Barbed Suture, Hysterectomy, Laparoscopy, Minimal Invasive
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 132 participants (estimated)
- Lead sponsor
- Aesculap AGIndustry (pharma, biotech, devices)
- Collaborators
- B.Braun Surgical SA
- Study start
- 19 Mar 2024 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 6 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate.
Secondly, the superiority of SYMMCORA®, mid-term unidirectional compared to the V-Loc®, unidirectional will be assessed regarding the mean time to close the vaginal cuff. The study will be performed in routine clinical setting, the only difference will be the randomization into two different suture groups. Both suture materials which will be applied to approximate the vaginal cuff are approved and carrying the CE-marks. Additionally, both sutures will be applied in their intended use. Neither additional invasive measures nor additional burden in regard to the patient will be performed.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SYMMCORA® | – | Device: Closure of the Vaginal Cuff after Total HysterectomyBarbed suture SYMMCORA® used for the vaginal cuff closure in female patients undergoing total laparoscopic hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU). |
| V-Loc® | – | Device: Closure of the Vaginal Cuff after Total HysterectomyBarbed suture V-Loc® used for the vaginal cuff closure in female patients undergoing total laparoscopic hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU). |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Female patients undergoing an elective, laparoscopic total hysterectomy
Key inclusion criteria (3 listed)
- Females undergoing an elective, laparoscopic total hysterectomy
- Age ≥ 18 years
- Written informed consent
Key exclusion criteria (6 listed)
- Emergency surgery
- Open surgery
- Patients undergone immunosuppressive drug treatment within the prior 6 months
- Patients with hypersensitivity or allergy to the suture material.
- Participation in another clinical study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Closure of the Vaginal Cuff after Total HysterectomyAlso: SuturingClosure of the vaginal cuff in patients undergoing laparoscopic total hysterectomy. The product under investigation and the comparator suture material will be used in routine clinical practice and according to the Instructions for Use (IfU). | Device | SYMMCORA®, V-Loc® |
Primary outcome
Suturing time to close the vaginal cuff
Time frame: intraoperatively
Measured in Minutes. Time to perform the vaginal cuff closure after laparoscopic total hysterectomy using a stop watch. Time starts when the needle passes the first time the tissue and ends after completion of the wound closure (cut of the needle from the thread).
16 secondary outcomes
Number of patients with early complications
Time frame: at discharge (up to 10 days after surgery)
Number of patients with complications over the study period
Time frame: at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Number of patients with device deficiencies over the study period
Time frame: intraoperatively, at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Patient satisfaction (VAS 0-100) over time
Time frame: at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Progress of Female Sexual Function Index (FSFI) compared to baseline
Time frame: Preoperatively (baseline), at follow-up visits 6-8 weeks postoperatively and 6 months postoperatively
Overall operation time
Time frame: intraoperatively
Cost of treatment
Time frame: at discharge (approximately 10 days after surgery)
Length of postoperative hospital stay
Time frame: at discharge (approximately 10 days after surgery)
Progress of Patient's abdominal pain (VAS 0-100) compared to baseline
Time frame: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Progress of Patient's pelvic pain (VAS 0-100) compared to baseline
Time frame: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Progress of Patient's lumbar pain (VAS 0-100) compared to baseline
Time frame: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Progress of General Health Status compared to baseline
Time frame: preoperatively (baseline) and at discharge (up to 10 days after surgery), 6-8 weeks postoperatively, 6 months postoperatively
Patient assessment of postoperative Dyspareunia
Time frame: at both follow-up visits (6-8 weeks postoperatively and 6 months postoperatively)
Assessment of the handling of the barbed suture (SYMMCORA®)
Time frame: intraoperatively
Assessment of the handling of the barbed suture (SYMMCORA®) compared to conventional suture
Time frame: intraoperatively
Assessment of the handling of the barbed suture (SYMMCORA®) compared to barbed suture (V-Loc)
Time frame: intraoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
- Derived from this study: PubMed 39806425Baumann P, Sanchez LH, Garcia NG, Sologiuc L, Hornemann A. Assessment of a novel unidirectional mid-term absorbable barbed suture versus a competitor barbed suture for vaginal cuff closure after gynaecology surgery, study protocol of a randomized controlled trial - BARHYSTER. BMC Surg. 2025 Jan 14;25(1):23. doi: 10.1186/s12893-024-02700-z.
- Individual participant dataSharing planned: No
Related trials for Abnormal Uterine Bleeding
Recruiting
Clinical Impact of Uterine Repair During Cesarean Section With Barbed Suture on the Incidence of Isthmocele
Isthmocele, Cesarean Scar Defect
Recruiting
A Clinical Study of the Aqua Therapeutics Thermal Therapy Vapor Ablation System in Premenopausal Women With Abnormal Uterine Bleeding
Menorrhagia
Enrolling by invitationPhase 1
Combined Ketorolac and Lidocaine Paracervical Block for Office Hysteroscopy
Abnormal Uterine Bleeding, Analgesia
RecruitingObservational study
Association of Ultrasound Features of the Myometrium Suggestive of Adenomyosis and Clinical Symptoms
Adenomyosis of Uterus
Recruiting
Office Hysteroscopy in Postmenopausal Women: A Randomized Trial of Cervical Preparation Strategies
Postmenopausal Women, Intrauterine Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Amadeus Hornemann, Prof. Dr. principal investigator
Klinikum Sachsenhausen der DGD
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Abnormal Uterine Bleeding and Endometriosis, run by Aesculap AG at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Germany, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Petra Baumann (+49746195 ext. 1646, petra.baumann@aesculap.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Suturing time to close the vaginal cuff (time frame: intraoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06024109, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.